Actinogen Medical Limited · ASX:ACW
Actinogen Medical — Non-Deal Roadshow (July 2015)
21 slides from Actinogen Medical's roadshow presentation, Jul 7, 2015
Slide 1: Developing Xanamem for Alzheimer's Dementia
Developing Xanamem™ for Alzheimer’s Dementia For personal use only Dr. Bill Ketelbey CEO and Managing Director, Actinogen Medical Biotech & Healthcare Investor Roadshow Melbourne & Sydney – July 2015
Slide 2: Forward Statements
Forward Statements For personal use only This presentation has been prepared by Actinogen Limited. (“Actinogen” or the “Company”) based on information available to it as at the date of this presentation. The information in this presentation is provided in summary form and does not contain all inform
Slide 3: Alzheimer's - a significant unmet need
Alzheimer's - a significant unmet need For personal use only Alzheimer’s disease is emerging as one of the most significant health challenges of our time • A person develops AD almost every minute in the US¹ • AD is the second leading cause of death in Australia behind ischaemic heart disease • Esti
Slide 4: Xanamem
Xanamem™ For personal use only In development as a treatment for Alzheimer's disease and prodromal Alzheimer's/mild cognitive impairment • A novel mechanism of action blocking the production of cortisol (the stress hormone) in the brain • Excess cortisol associated with reversible memory loss, amylo
Slide 5: Mechanism of action - a key differentiator
Mechanism of action - a key differentiator For personal use only Xanamem™’s novel mechanism of action sets it apart from other AD treatments 5
Slide 6: Pre-clinical data
Pre-clinical data For personal use only Xanamem™- a highly selective HSD1 inhibitor in pre-clinical animal models. • Inhibition of HSD1 improves cognition in ageing and AD models • Inhibition of HSD1 reduces Aβ plaque burden and plasma Aβ in AD models 6
Slide 7: Xanamem development milestones
Xanamem™ development milestones For personal use only Phase II efficacy Second study in patients Phase I Results for Phase I with AD and Mild trial trial and final Cognitive completed preclinical study Impairment pending EARLY-2015 MID-2015 2016 Final Establishment of Phase II pre-clinical Xanamem
Slide 8: Xanamem Clinical Advisory Board
TM Xanamem Clinical Advisory Board For personal use only Powerhouse Advisory Board to drive Xanamem™’s clinical development. World experts to help design the optimum Phase II efficacy trial for Xanamem™ in early and prodromal Alzheimer’s patients Prof. Craig Ritchie Prof. Colin Masters Prof. Jeffrey
Slide 9: Xanamem Ph II clinical development
Xanamem™ Ph II clinical development Edinburgh June 2015 For personal use only Left-right: Prof Craig Ritchie, Prof Brain Walker, Prof Colin Masters, Martin Rogers, Dr Bill Ketelbey (and mascot), Vincent Ruffles, Dr Scott Webster, Prof Jonathan Seckl. Absent: Prof Jeff Cummings. The Alzheimer's Phase
Slide 10: Xanamem pipeline
Xanamem™ pipeline For personal use only Xanamem™’s novel mechanism of action – blocking excess cortisol production – offers many additional possible applications relevant to diseases of the central nervous and endocrine/metabolic systems • Potential development opportunities: – PTSD (post traumatic
Slide 11: Investment highlights
Investment highlights For personal use only • Xanamem™ a potential treatment for early and prodromal AD/mild cognitive impairment • Significant unmet need in a huge and growing global market • Novel mechanism of action, targeting the stress hormone cortisol – a key differentiator • Hypothesis backed
Slide 12: Financial profile
Financial profile For personal use only Price (AUD) Key Corporate Data: $0.16 Market Cap.⃰⃰⃰⃰ ~$46m $0.14 Share Price⃰⃰ $0.076 $0.12 Cash** $10.4m $0.10 Shares on issue^ 606.16m $0.08 ⃰⃰ market cap and share price data as of July 3, $0.06 2015 **includes the proceeds from the Placement and $0.04 SPP
Slide 13: Board and Management
Board and Management For personal use only A highly experienced Board and Management team with a wealth of drug development, commercialisation and clinical research expertise Martin Rogers • Biotechnology entrepreneur and executive Chairman • Non-Executive Director of OncoSil (ASX:OSL), Chair of Rhi
Slide 14: Contact details
Contact details For personal use only Head Office Level 9, Suite 1 68 Pitt Street Sydney NSW 2000 Telephone: +61 (02) 8964 7401 Facsimile: +61 (02) 8964 7588 Email: [email protected] Twitter: @billketelbey 14
Slide 15: Thank you and questions
For personal use only Thank you and questions
Slide 16: Appendix
For personal use only Appendix
Slide 17: A boom in brain medicine
A boom in brain medicine For personal use only • People are living longer and healthier lives due to innovations in preventing and treating cardiovascular disease, cancer and infectious disease. Now the focus is on the brain and brain medicines. • Last year investors poured US$3.3 billion into firms
Slide 18: Alzheimer's at the forefront of the boom
Alzheimer’s at the forefront of the boom For personal use only • Alzheimer’s represents the biggest market potential – by 2050 Alzheimer's will cost $1tn annually in the US alone. • The pharmaceutical industry bet big on injectable medicines to prevent or reverse Alzheimer’s by attacking the build-u
Slide 19: Major advances in understanding and diagnosing Alzheimer's
Major advances in understanding and diagnosing Alzheimer’s For personal use only • Understanding the life course of the disease • Understanding of the pathology of the disease and how best to impact it • Brain imaging technology 19
Slide 20: Major advances in understanding and diagnosing Alzheimer's
Major advances in understanding and diagnosing Alzheimer’s For personal use only • Our ability to detect, diagnose and treat the condition much earlier 20
Slide 21: Significant Market interest in Alzheimer's peer companies
Significant Market interest in Alzheimer’s peer companies For personal use only • Avanir Pharmaceuticals (NASDAQ:AVNR) – Jan 2015: US$3.5bn buy-out by Otsuka Pharma following positive Phase II data on AVP-923 for symptomatic treatment of behavioural symptoms in Alzheimer's patients. Avanir stock tra